| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803111201025 | 311120102 | ATESTUR SOFT.CAPS 0.5MG/CAP BTx30 σε Transparent triplex (PVC-PE-PVCD)/Aluminium blister | 4.88 | 5.12 | 07.05 |
| 05/2018 | 2803111201056 | 311120105 | ATESTUR SOFT.CAPS 0.5MG/CAP BTx90 σε Transparent triplex (PVC-PE-PVCD)/Aluminium blister | 19.78 | 20.75 | 28.60 |
For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery.
Dutasteride inhibits the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under <i>in vitro</i> and <i>in vivo</i> conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor.
60%
5 weeks
Dutasteride is extensively metabolized in humans. Dutasteride and its metabolites were excreted mainly in feces.
* 300 to 500 L